TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03635528

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 5
Description: Biofinity multifocal D Lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 5
Description: Biofinity multifocal D Lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 5
Description: Biofinity multifocal D Lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 5
Description: Biofinity multifocal D Lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 5
Description: Biofinity multifocal D Lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 5
Description: Biofinity multifocal D Lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 5
Description: Biofinity multifocal D Lens
Study: NCT02111200

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Benzoate
Description: Subjects will be instructed to take the study medication with meals (08:00 breakfast; 13:00 lunch; 19:00 dinner) for 3 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Phenylbutyrate
Description: Subjects will be instructed to take the study medication with meals (08:00 breakfast; 13:00 lunch; 19:00 dinner) for 3 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Phenylbutyrate
Description: Subjects will be instructed to take the study medication with meals (08:00 breakfast; 13:00 lunch; 19:00 dinner) for 3 days.
Study: NCT03635528

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 5
Description: Biofinity multifocal D Lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 5
Description: Biofinity multifocal D Lens
Study: NCT00111761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Part 1: 125 mg/m\^2 IV infusion once a week on weeks 1 through 4 of each 6-week treatment cycle. Part 2: 180 mg/m\^2 IV infusion every other week until disease progression or unable to tolerate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Part 1: 125 mg/m\^2 IV infusion once a week on weeks 1 through 4 of each 6-week treatment cycle. Part 2: 180 mg/m\^2 IV infusion every other week until disease progression or unable to tolerate.
Study: NCT03635528

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control Lens 1
Description: EMO-117

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control Lens 1
Description: EMO-117

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control Lens 1
Description: EMO-117

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control Lens 1
Description: EMO-117

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control Lens 1
Description: EMO-117
Study: NCT00111761

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Intravenous (IV) infusions of panitumumab 2.5 mg/kg once a week delivered in 6-week cycles.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Intravenous (IV) infusions of panitumumab 2.5 mg/kg once a week delivered in 6-week cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Part 1: IV bolus 500 mg/m\^2 on weeks 1 through 4 of each 6-week cycle. Part 2: IV bolus 400 mg/m\^2 and infusional 2400-3000 mg/m\^2 over 46 hours once every other week until disease progression or unable to tolerate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Part 1: IV bolus 500 mg/m\^2 on weeks 1 through 4 of each 6-week cycle. Part 2: IV bolus 400 mg/m\^2 and infusional 2400-3000 mg/m\^2 over 46 hours once every other week until disease progression or unable to tolerate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Part 1: IV bolus 20 mg/m\^2 on weeks 1 through 4 of each 6-week cycle. Part 2: 400 mg/m\^2 every other week until disease progression or unable to tolerate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Part 1: IV bolus 20 mg/m\^2 on weeks 1 through 4 of each 6-week cycle. Part 2: 400 mg/m\^2 every other week until disease progression or unable to tolerate.
Study: NCT03635528

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control Lens 1
Description: EMO-117

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control Lens 1
Description: EMO-117

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control Lens 1
Description: EMO-117

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control Lens 1
Description: EMO-117

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control Lens 1
Description: EMO-117

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control Lens 1
Description: EMO-117

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control Lens 1
Description: EMO-117

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control Lens 1
Description: EMO-117

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control Lens 1
Description: EMO-117

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control Lens 2
Description: Proclear 1 day

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control Lens 2
Description: Proclear 1 day

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control Lens 2
Description: Proclear 1 day
Study: NCT00513929

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc sulphate
Description: Arm X : Zinc sulphate 10 mg will be given orally twice a day since admission to resolution of pneumonia episode in addition to standard antibiotic treatment.
Study: NCT00373503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lofexidine
Description: alpha 2 adrenergic agonist, hypothesized to decrease noradrenergic activity
Study: NCT03635528

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control Lens 2
Description: Proclear 1 day

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control Lens 2
Description: Proclear 1 day

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control Lens 2
Description: Proclear 1 day

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control Lens 2
Description: Proclear 1 day

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control Lens 2
Description: Proclear 1 day

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control Lens 2
Description: Proclear 1 day

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control Lens 2
Description: Proclear 1 day

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control Lens 2
Description: Proclear 1 day

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control Lens 2
Description: Proclear 1 day

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control Lens 2
Description: Proclear 1 day

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control Lens 2
Description: Proclear 1 day
Study: NCT03828643

Intervention type: DRUG
Intervention: Secukinumab
Description: Secukinumab 300 mg without loading dose at weeks 0, 1, 2, 3 and 4.

Intervention type: DRUG
Intervention: Secukinumab
Description: Secukinumab 300 mg with loading dose at weeks 0, 1, 2, 3 and 4.
Study: NCT02233543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QVA149
Description: Delivered once daily via single-dose dry powder inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QVA149
Description: Delivered once daily via single-dose dry powder inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QVA149 Placebo
Description: Placebo delivered once daily via single-dose dry powder inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QVA149 Placebo
Description: Placebo delivered once daily via single-dose dry powder inhaler
Study: NCT03206892

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laparoscopic ovarian drilling
Description: laparoscopic ovarian drilling for polycystic ovary syndrome in infertile women comparing LESS surgery to conventional multiport laparoscopy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic ovarian drilling
Description: laparoscopic ovarian drilling for polycystic ovary syndrome in infertile women comparing LESS surgery to conventional multiport laparoscopy
Study: NCT00373503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dronabinol
Description: cannabinoid agonist hypothesized to decrease MJ withdrawal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marijuana
Description: marijuana intoxication, withdrawal and relapse assessed
Study: NCT00091078

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: oblimersen sodium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: Given orally
Study: NCT00682747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen
Description: 40 treatments with hyperbaric oxygen once per day, five days per week, 2.4 ATA, 100 % oxygen (10-15 minutes compression with air, 90 min of oxygen breathing - two 10 minutes break for breathing air after each 30 minutes of oxygen, 10 minutes decompression with oxygen
Study: NCT04165876

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Primary Motor Cortex Stimulation
Description: Using the Starstim 32, HD-tDCS equipment we provide 20 minutes of 2 mA anodal stimulation of primary motor cortex (M1) using a ring-cathode configuration
Study: NCT00091078

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT04165876

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dorsolateral Prefrontal Cortex Stimulation
Description: Using the Starstim 32, HD-tDCS equipment we provide 20 minutes of 2 mA anodal stimulation of dorsolateral prefrontal cortex (DLPFC) using a ring-cathode configuration

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Multimodal Stimulation (DLPFC+M1)
Description: Using the Starstim 32, HD-tDCS equipment we provide 20 minutes of 2 mA anodal multimodal stimulation of dorsolateral prefrontal cortex (DLPFC) and primary motor cortex simultaneously using ring-cathode configurations around the two anodes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: Using the Starstim 32, HD-tDCS equipment we provide sham stimulation with 30 seconds of ramping up to 2 mA intensity, then turning off for 19 minutes and then ramping down from 2 mA intensity to 0 in the last 30 seconds.
Study: NCT04330924

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Create Real-life Experience And Teamwork In Virtual Environment (CREATIVE)
Description: 3D virtual hospital environment where participants can perform physical and social interaction and presence using avatars.
Study: NCT02480959

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgical treatment for recurrent patellar instability
Description: Either medial plication or MPFL reconstructuion surgery

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgical treatment for recurrent patellar instability
Description: Either medial plication or MPFL reconstructuion surgery
Study: NCT00266227

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Oral or parenteral repeating dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: methotrexate
Description: Oral or parenteral repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: folate
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: folate
Description: Intravenous repeating dose
Study: NCT01378780

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational intervention for diet and physical activity
Description: The proposed project, SHARE, is a culturally-tailored, primary stroke prevention intervention for MAs and EAs that targets a number of health-related behaviors related to stroke risk. Using a combination of self-help materials, social support, peer counseling based on Motivational interviewing, tailored newsletters, and social environmental changes in Catholic Churches, the SHARE intervention will lead to increases in moderate and vigorous intensity physical activity, decreases in salt intake, and increases in fruit and vegetable intake. Additional targets include decreases in BMI for those overweight or obese, reduction of dietary fat (trans, saturated and total fat), and increases in low-fat dairy products, changes that will serve to reduce blood pressure and stroke risk. Additionally, SHARE will seek to improve hypertension medication adherence in participants with previously diagnosed high blood pressure at baseline screening.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Educational message on skin cancer awareness
Description: Control group will get the diet and physical activity intervention after the crossover but no outcomes will be measured after the crossover
Study: NCT01869387

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation
Study: NCT02272296

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: jet injector
Description: 1 administration of insulin in a dose of 0.2 units per kg body weight subcutaneously in the abdomen, 1 empty administration

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: jet injector
Description: 1 administration of insulin in a dose of 0.2 units per kg body weight subcutaneously in the abdomen, 1 empty administration

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: jet injector
Description: 1 administration of insulin in a dose of 0.2 units per kg body weight subcutaneously in the abdomen, 1 empty administration

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional pen (NovoPen IV)
Description: 1 administration of insulin in a dose of 0.2 units per kg body weight subcutaneously in the abdomen, 1 empty administration

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Conventional pen (NovoPen IV)
Description: 1 administration of insulin in a dose of 0.2 units per kg body weight subcutaneously in the abdomen, 1 empty administration
Study: NCT04576403

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: activated mittens
Description: activated mittens (with electronic heat)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: deactivated mittens
Description: deactivated mittens (without electronic heat)
Study: NCT03828747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semorinemab
Description: Participants will receive semorinemab every 2 weeks (Q2W) for the first three doses of the double-blind treatment period and every 4 weeks (Q4W) thereafter during the double-blind treatment period. Semorinemab will be administered Q4W in the OLE period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo every 2 weeks (Q2W) for the first three doses of the double-blind treatment period and every 4 weeks (Q4W) thereafter during the double-blind treatment period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: [18F]GTP1
Description: \[18F\]GTP1 will be administered as a solution for intravenous (IV) use, as part of positron emission tomography (PET) imaging.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]GTP1
Description: \[18F\]GTP1 will be administered as a solution for intravenous (IV) use, as part of positron emission tomography (PET) imaging.
Study: NCT00549393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% Chlorhexidine gluconate cloth
Description: Daily bathing
Study: NCT04007380

Intervention type: OTHER
Group type: OTHER
Intervention: Continuous positive airway pressure (CPAP) therapy
Description: The participants will undergo CPAP therapy for 4 consecutive months in the management of moderate-to-severe SRBDs
Study: NCT04321668

Intervention type: DEVICE
Group type: OTHER
Intervention: Synvisc-One
Description: SYNVISC-ONE® (Hylan G-F 20), 10 mL single-injection viscosupplement Status : CE marked (CE 0086) class III Medical Device The IP is used according to its usual dosage, administration and indication
Study: NCT03387748

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gesture elicitation
Description: * Participants are required to gesture with their hands (and not speaking) one by one 30 pictures from the Boston Naming Task which appear on a laptop screen.~* Participants retell a cartoon to the researcher~* The researcher initiates a 10-min spontaneous conversation.~These three tasks are video-recorded.
Study: NCT03760731

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy for Moral Injury (ACT-MI)
Description: Acceptance and Commitment Therapy for Moral Injury (ACT-MI) is a novel treatment protocol detailing the application of ACT for recovery from moral injury. ACT-MI is designed to help Veterans learn to interact differently with moral emotions and engage meaningfully in their lives. The intervention is group-based and spans twelve, 90-minute sessions. The current ACT-MI protocol was developed through an iterative process in which authors generated and refined the intervention based on clinical interactions with Veterans currently reporting moral injury.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Present Centered Therapy (PCT)
Description: Present Centered Therapy (PCT) will include 12 group sessions, but will focus on problem solving daily life difficulties related to moral injury rather than the experiential focus on moral emotions presented in ACT-MI. Because PCT has been established as an evidence-based active control condition, it is likely to serve as a beneficial transdiagnostic intervention in its own right.
Study: NCT02593721

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Median Nerve Neural Mobilization
Description: Non-surgical non-invasive Median Nerve neural mobilization procedure was applied by a physical therapist continuously during 2 minutes in 5 different occasions with 1 minute of rest between each 2 minute application of the Neural Mobilization technique. The intervention was applied during a period of 6 weeks. The maximum level of elbow extension movement degree without the reproduction of symptoms during the application of the Median Nerve Neural mobilization treatment was determined through the baseline use of a Universal Goniometer Device.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: The active comparator group received an oral Ibuprofen treatment. The starting dose was of 400 mg/day and it was increased to a maximum of 1200 mg/day divided in 3 oral intakes every 8 hours depending on patient tolerance.The intervention was applied during a period of 6 weeks.
Study: NCT00229437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-128
Description: TAK-128 5 mg, tablets, orally, once daily for up to 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-128
Description: TAK-128 50 mg, tablets, orally, once daily for up to 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-128
Description: TAK-128 100 mg, tablets, orally, once daily for up to 6 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TAK-128 placebo-matching tablets, orally, once daily for up to 6 months.
Study: NCT02796300

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bioflo Dialysis Catheter
Description: The catheter placement procedure will be performed in the interventional radiology suite. The catheter will be inserted subcutaneously through incision in the chest through the tract.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Palindrome Dialysis Catheter
Description: The catheter placement procedure will be performed in the interventional radiology suite. The catheter will be inserted subcutaneously through incision in the chest through the tract.
Study: NCT02241005

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Theraworx™ bath wipes
Description: Theraworx™ bath wipes will be supplied in packaging similar to the standard bath wipes used in this study. The bath wipes will be started on the day of admission, and used once daily for a period of 60 days post-HSCT.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard bath wipes
Description: Standard bath wipes will be supplied in packaging similar to the Theraworx™ bath wipes used in this study. The bath wipes will be started on the day of admission, and used once daily for a period of 60 days post-HSCT.
Study: NCT04245774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine (as Levobupivacaine Hydrochloride) 75 Mg/10 mL Solution for Injection Ampoule
Description: 7,5 mg (1.5 mL) of 0,5% hyperbaric levobupivacaine (1 mL 0.75% isobaric levobupivacaine (Chirocaine® 75 mg/10mL ampoule Abbott/Turkey, Nycomed Pharma/Norway) plus 0.24 mL 50% Dextrose (dextrose 120 mg) (Eczacıbaşı/Turkey) and 0.26 mL distilled water) injected into the intrathecal space in sitting position through L4-L5 or L5-S1 intervertebral space in 30 seconds. All patients kept in sitting position for 5 minutes with aid after intrathecal injection and than layed in supine position, finally they positioned in prone jack-knife.
Study: NCT02698605

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Usability test study of the MirrorPath
Description: The study was conducted by research assistants. Each subject received one assessment that last lasted 30 minutes. The subjects were not paid for participation. In that, no randomization or masking were performed. Prior to the experiment part of the study, the subjects provided basic biographical information. We then explained the experimental process and demonstrated the operation of the device.~A novel rehabilitation device, the MirrorPath, designed for the upper limb rehabilitation of patients with hemiplegic stroke. The MirrorPath that was 1180x440x300mm in size and had a shell was constructed of acrylonitrile butadiene styrene (ABS). The control module featured an on/off switch, a knob for adjusting the speed, and an emergency cutoff switch.
Study: NCT04674696

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Approach
Description: Patients will receive 2 CAPOX cycles, followed by short-course radiotherapy and 4 CAPOX cycles.
Study: NCT03882541

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music therapy
Description: To evaluate the effect of music in patients anxiety and pain during perioperative process in surgical intervention with regional anaesthesia without sedatives or anxiolytics.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sedation with midazolam
Description: To evaluate the effect of sedation (in comparation with music group) in patients anxiety and pain durin perioperative process in surgical intervention with regional anesthesia without music